Saturday, July 11, 2026

Drug profile · INN

nepafenac

nepafenac (NEVANAC) is a cyclooxygenase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved EMA: approved Sensory organs (S01) S01BC10
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — nepafenac
US status
approved
Class
Sensory organs (S01)
Route
OPHTHALMIC
Patents
0
Programs
0
Data quality
0.84

Quick answer

nepafenac (NEVANAC) is a cyclooxygenase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN nepafenac
Brand NEVANAC
Mechanism Cyclooxygenase inhibitor
Target Cyclooxygenase
Therapeutic class Sensory organs (S01)
Route OPHTHALMIC
Formulation SUSPENSION/DROPS
ATC code S01BC10

Mechanism of action

Cyclooxygenase inhibitor

Primary target: Cyclooxygenase

Approval history

Authority Status Date
FDA approved
EMA approved

Related & competitor drugs

  1. aflibercept Sensory organs (S01)
  2. aspirin Cyclooxygenase inhibitor
  3. atropine sulfate Sensory organs (S01)
  4. bimatoprost Sensory organs (S01)
  5. bromfenac sodium Cyclooxygenase inhibitor
  6. diclofenac potassium Cyclooxygenase inhibitor

Frequently asked questions

What is nepafenac?

nepafenac (NEVANAC) is a cyclooxygenase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for nepafenac?

NEVANAC is a marketed brand name for nepafenac. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of nepafenac?

nepafenac has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.